These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

640 related items for PubMed ID: 26678359

  • 1. An mTOR-inhibitor-based protocol and calcineurin inhibitor (CNI)-free treatment in kidney transplant recipients from donors after cardiac death: good renal function, but high incidence of conversion to CNI.
    Sánchez-Escuredo A, Diekmann F, Revuelta I, Esforzado N, Ricart MJ, Cofán F, Torregrosa JV, Peri L, Ruiz Á, Campistol JM, Oppenheimer F.
    Transpl Int; 2016 Mar; 29(3):362-8. PubMed ID: 26678359
    [Abstract] [Full Text] [Related]

  • 2. Influence of delayed graft function and acute rejection on outcomes after kidney transplantation from donors after cardiac death.
    Nagaraja P, Roberts GW, Stephens M, Horvath S, Fialova J, Chavez R, Asderakis A, Kaposztas Z.
    Transplantation; 2012 Dec 27; 94(12):1218-23. PubMed ID: 23154212
    [Abstract] [Full Text] [Related]

  • 3. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?
    Höcker B, Tönshoff B.
    Paediatr Drugs; 2011 Feb 01; 13(1):49-69. PubMed ID: 21162600
    [Abstract] [Full Text] [Related]

  • 4. Polyclonal versus monoclonal induction therapy in a calcineurin inhibitor-free immunosuppressive therapy in renal transplantation: a comparison of efficacy and costs.
    Sánchez-Escuredo A, Alsina A, Diekmann F, Revuelta I, Esforzado N, Ricart MJ, Cofan F, Fernandez E, Campistol JM, Oppenheimer F.
    Transplant Proc; 2015 Feb 01; 47(1):45-9. PubMed ID: 25645767
    [Abstract] [Full Text] [Related]

  • 5. Renal function in heart transplant patients after switch to combined mammalian target of rapamycin inhibitor and calcineurin inhibitor therapy.
    Helmschrott M, Rivinius R, Bruckner T, Katus HA, Doesch AO.
    Drug Des Devel Ther; 2017 Feb 01; 11():1673-1680. PubMed ID: 28652705
    [Abstract] [Full Text] [Related]

  • 6. Immunosuppressive minimization with mTOR inhibitors and belatacept.
    Diekmann F.
    Transpl Int; 2015 Aug 01; 28(8):921-7. PubMed ID: 25959589
    [Abstract] [Full Text] [Related]

  • 7. Influence of sirolimus on proteinuria in de novo kidney transplantation with expanded criteria donors: comparison of two CNI-free protocols.
    Diekmann F, Gutiérrez-Dalmau A, López S, Cofán F, Esforzado N, Ricart MJ, Rossich E, Saval N, Torregrosa JV, Oppenheimer F, Campistol JM.
    Nephrol Dial Transplant; 2007 Aug 01; 22(8):2316-21. PubMed ID: 17452413
    [Abstract] [Full Text] [Related]

  • 8. mTOR inhibitor versus mycophenolic acid as the primary immunosuppression regime combined with calcineurin inhibitor for kidney transplant recipients: a meta-analysis.
    Xie X, Jiang Y, Lai X, Xiang S, Shou Z, Chen J.
    BMC Nephrol; 2015 Jul 01; 16():91. PubMed ID: 26126806
    [Abstract] [Full Text] [Related]

  • 9. mTOR inhibitor monotherapy. A good treatment choice in renal transplantation?
    Franco-Esteve A, Tordera D, de la Sen ML, Jiménez L, Mas P, Muñoz C, Olivares J.
    Nefrologia; 2012 Jul 01; 32(5):631-8. PubMed ID: 23013949
    [Abstract] [Full Text] [Related]

  • 10. Kidney transplantation from donation after cardiac death donors: lack of impact of delayed graft function on post-transplant outcomes.
    Singh RP, Farney AC, Rogers J, Zuckerman J, Reeves-Daniel A, Hartmann E, Iskandar S, Adams P, Stratta RJ.
    Clin Transplant; 2011 Jul 01; 25(2):255-64. PubMed ID: 20331689
    [Abstract] [Full Text] [Related]

  • 11. Antithymocyte globulin induction and rapid steroid taper leads to excellent results in kidney transplantation with donation after cardiac death donors: importance of rejection and delayed graft function.
    Mai ML, Mai WK, Taner CB, Prendergast MB, Wadei HM, Gonwa TA.
    Transplant Proc; 2013 May 01; 45(4):1528-30. PubMed ID: 23726612
    [Abstract] [Full Text] [Related]

  • 12. Long-Term Renal Function in Liver Transplant Recipients After Conversion From Calcineurin Inhibitors to mTOR Inhibitors.
    Hüsing A, Schmidt M, Beckebaum S, Cicinnati VR, Koch R, Thölking G, Stella J, Heinzow H, Schmidt HH, Kabar I.
    Ann Transplant; 2015 Nov 26; 20():707-13. PubMed ID: 26608590
    [Abstract] [Full Text] [Related]

  • 13. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS, Irfan Saeed M, Ranganna K, Malat G, Sustento-Reodica N, Kumar AM, Meyers WC.
    Transpl Immunol; 2008 Nov 26; 20(1-2):32-42. PubMed ID: 18773960
    [Abstract] [Full Text] [Related]

  • 14. Impact of calcineurin-inhibitor conversion to mTOR inhibitor on renal allograft function in a prednisone-free regimen.
    Chhabra D, Alvarado A, Dalal P, Leventhal J, Wang C, Sustento-Reodica N, Najafian N, Skaro A, Levitsky J, Mas V, Gallon L.
    Am J Transplant; 2013 Nov 26; 13(11):2902-11. PubMed ID: 24007570
    [Abstract] [Full Text] [Related]

  • 15. Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial.
    Grinyó JM, Del Carmen Rial M, Alberu J, Steinberg SM, Manfro RC, Nainan G, Vincenti F, Jones-Burton C, Kamar N.
    Am J Kidney Dis; 2017 May 26; 69(5):587-594. PubMed ID: 27889299
    [Abstract] [Full Text] [Related]

  • 16. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.
    Jaber JJ, Feustel PJ, Elbahloul O, Conti AD, Gallichio MH, Conti DJ.
    Clin Transplant; 2007 May 26; 21(1):101-9. PubMed ID: 17302598
    [Abstract] [Full Text] [Related]

  • 17. Mycophenolate and sirolimus as calcineurin inhibitor-free immunosuppression improves renal function better than calcineurin inhibitor-reduction in late cardiac transplant recipients with chronic renal failure.
    Groetzner J, Kaczmarek I, Schulz U, Stegemann E, Kaiser K, Wittwer T, Schirmer J, Voss M, Strauch J, Wahlers T, Sohn HY, Wagner F, Tenderich G, Stempfle HU, Mueller-Ehmsen J, Schmid C, Vogeser M, Koch KC, Reichenspurner H, Daebritz S, Meiser B, Reichart B, VENINAHTx-Investigators.
    Transplantation; 2009 Mar 15; 87(5):726-33. PubMed ID: 19295318
    [Abstract] [Full Text] [Related]

  • 18. A Randomized 2x2 Factorial Clinical Trial of Renal Transplantation: Steroid-Free Maintenance Immunosuppression with Calcineurin Inhibitor Withdrawal after Six Months Associates with Improved Renal Function and Reduced Chronic Histopathology.
    Stevens RB, Foster KW, Miles CD, Kalil AC, Florescu DF, Sandoz JP, Rigley TH, Malik T, Wrenshall LE.
    PLoS One; 2015 Mar 15; 10(10):e0139247. PubMed ID: 26465152
    [Abstract] [Full Text] [Related]

  • 19. mTOR inhibitor-associated proteinuria in kidney transplant recipients.
    Diekmann F, Andrés A, Oppenheimer F.
    Transplant Rev (Orlando); 2012 Jan 15; 26(1):27-9. PubMed ID: 22137729
    [Abstract] [Full Text] [Related]

  • 20. The impact of kidney donor profile index on delayed graft function and transplant outcomes: A single-center analysis.
    Zens TJ, Danobeitia JS, Leverson G, Chlebeck PJ, Zitur LJ, Redfield RR, D'Alessandro AM, Odorico S, Kaufman DB, Fernandez LA.
    Clin Transplant; 2018 Mar 15; 32(3):e13190. PubMed ID: 29314286
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.